Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The Philadelphia, PA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol ONCE. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
